News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Fights With Pediatrician Group Over Preemie Drug Guidelines



7/29/2014 6:22:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Once again, there is controversy over an expensive drug for premature babies.

At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca 'sAZN.LN -0.23% MedImmune unit, because evidence shows the medicine benefits few children other than the youngest premature infants.

Help employers find you! Check out all the jobs and post your resume.

Read at Wall Street Journal
Read at CBS News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES